医药6大赛道横向对比
496家上市公司 · 按评分排名 · 数据口径:2025年报
6大赛道总览
| 赛道 | 公司数 | 评分中位 | 毛利率中位 | 净利率中位 | 亏损数 | 健康度 |
| 化学制药 | 154 | 54 | 48.2% | 6.3% | 44 | 承压 |
| 医疗器械 | 137 | 57 | 52.6% | 9.5% | 35 | 承压 |
| 中药Ⅱ | 68 | 55 | 54.3% | 7.2% | 14 | 承压 |
| 生物制品 | 55 | 52 | 69.5% | 5.5% | 20 | 承压 |
| 医疗服务 | 49 | 57 | 34.7% | 6.9% | 14 | 承压 |
| 医药商业 | 33 | 52 | 11.0% | 1.3% | 7 | 承压 |
对比结论:医疗器械(57)= 医疗服务(57)> 中药(55)> 化学制药(54)> 生物制品(52)= 医药商业(52),是 2025 年医药行业的评分梯队。但这个排名最该读的不是名次,而是「同一门类里的四种生意」:医疗器械(净利率中位 9.5%、研发 10.4%)是纯制造,成本语言与机械制造同构;医疗服务(管理费率 12.2%、销售费率 4.7%)是服务型,人力与设备通量就是毛利;中药(销售费率 31.8%、研发 3.9%)是品牌驱动,钱花在渠道上;化学制药(研发 7.2%)内部还要再分制剂与原料药两条完全不同的成本语言;生物制品(毛利 69.5%、销售 30.1%、研发 12.2%、现金周期 271 天)是高投入高毛利的组合;医药商业(成本率 89.0%、净利率 1.3%、黄金线 0/33)是薄利快周转的分销。同一句「净利率 8% 是及格线」,在医疗器械是 53% 公司达标(73/137)、在医药商业是 0% 达标(0/33)——这是本平台坚持按申万二级分组、组内分位的直接原因。三生国健(87 分)、安杰思(87)、药明康德(85)、桂林三金(85)、惠泰医疗(82)居前;多瑞医药(14 分)、维康药业(14)、禾元生物(15)、和元生物(15)、达安基因(16)沉底——注意底部的两类公司要分开读:经营承压型(毛利与净利同步下滑)与临床期创新药(研发价值尚未兑现)。对医药行业的成本管理者,这份排名说明三件事:①单品种成本核算到批号(集采倒推成本上限)②销售与研发两笔投入的产出效率(不是压缩,是提高产出)③现金转化(全行业现金周期中位 120 天、生物制品 271 天)——这三件事加起来的分量,远超过传统的「采购降价」。
化学制药(154家)
赛道画像:化学制剂与原料药——制剂高毛利拼集采成本,原料药是大宗化工制造(成本率中位 51.1%)。评分中位54分,毛利率中位48.2%,净利率中位6.3%,44家亏损。
| # | 公司 | 毛利率 | 净利率 | 研发费率 | 销售费率 | 评分 | 等级 |
|---|
| 1 | 华特达因 | 85.1% | 24.0% | 4.1% | 22.1% | 80分 | A- |
| 2 | 德源药业 | 84.1% | 22.4% | 11.4% | 41.7% | 79分 | A- |
| 3 | 小方制药 | 65.0% | 39.5% | 3.7% | 11.3% | 77分 | A- |
| 4 | 兴齐眼药 | 81.2% | 28.1% | 9.1% | 30.9% | 75分 | A- |
| 5 | 赛分科技 | 71.4% | 31.4% | 13.7% | 10.8% | 74分 | B+ |
| 6 | 奥锐特 | 59.7% | 26.5% | 9.0% | 7.7% | 73分 | B+ |
| 7 | 立方制药 | 64.6% | 10.6% | 7.1% | 42.1% | 72分 | B+ |
| 8 | 翰宇药业 | 58.4% | 3.8% | 13.1% | 11.1% | 72分 | B+ |
| 9 | 百济神州 | 87.6% | 3.8% | 40.6% | 27.7% | 71分 | B+ |
| 10 | 艾力斯 | 96.8% | 42.2% | 8.0% | 40.0% | 71分 | B+ |
| 11 | 卫信康 | 61.5% | 20.5% | 9.7% | 19.9% | 71分 | B+ |
| 12 | 星昊医药 | 70.0% | 15.8% | 11.6% | 34.4% | 70分 | B+ |
| 13 | 海昇药业 | 42.9% | 31.5% | 4.8% | 1.2% | 70分 | B+ |
| 14 | 奥翔药业 | 53.5% | 16.5% | 21.2% | 2.6% | 70分 | B+ |
| 15 | 康弘药业 | 89.8% | 25.4% | 11.6% | 37.5% | 70分 | B+ |
| 16 | 恒瑞医药 | 86.2% | 24.4% | 22.0% | 28.8% | 69分 | B+ |
| 17 | 丽珠集团 | 65.9% | 16.8% | 7.8% | 29.8% | 69分 | B+ |
| 18 | 森萱医药 | 46.6% | 23.8% | 5.6% | 2.6% | 68分 | B+ |
| 19 | 吉贝尔 | 89.5% | 27.1% | 4.2% | 50.8% | 68分 | B+ |
| 20 | 海欣股份 | 59.2% | 23.2% | 3.1% | 30.6% | 68分 | B+ |
| 21 | 易明医药 | 82.1% | 14.6% | 2.3% | 54.5% | 67分 | B+ |
| 22 | 圣诺生物 | 57.7% | 21.3% | 7.4% | 7.8% | 66分 | B+ |
| 23 | 华海药业 | 60.2% | 3.1% | 14.3% | 18.4% | 66分 | B+ |
| 24 | 福元医药 | 65.5% | 13.4% | 11.5% | 34.2% | 66分 | B+ |
| 25 | 新赣江 | 44.9% | 10.3% | 11.3% | 6.5% | 65分 | B+ |
| 26 | 微芯生物 | 87.1% | 5.6% | 24.4% | 41.9% | 65分 | B+ |
| 27 | 恩华药业 | 72.1% | 17.9% | 11.6% | 35.8% | 65分 | B+ |
| 28 | 贝达药业 | 79.5% | 8.5% | 14.2% | 36.0% | 65分 | B+ |
| 29 | 新天地 | 34.9% | 18.0% | 6.9% | 0.8% | 65分 | B+ |
| 30 | 川宁生物 | 29.3% | 16.7% | 2.2% | 0.6% | 65分 | B+ |
| 31 | 诚意药业 | 69.8% | 24.0% | 5.5% | 24.1% | 64分 | B |
| 32 | 海森药业 | 45.6% | 25.5% | 7.3% | 3.0% | 64分 | B |
| 33 | 纳微科技 | 71.3% | 14.7% | 21.3% | 17.3% | 63分 | B |
| 34 | 健康元 | 62.4% | 8.8% | 8.4% | 27.3% | 63分 | B |
| 35 | 中 关 村 | 59.3% | 2.0% | 4.1% | 36.9% | 63分 | B |
| 36 | 京新药业 | 50.1% | 18.6% | 9.0% | 14.8% | 63分 | B |
| 37 | 千红制药 | 58.4% | 25.4% | 7.0% | 20.2% | 63分 | B |
| 38 | 民生健康 | 51.1% | 15.2% | 3.3% | 27.5% | 63分 | B |
| 39 | 上海谊众 | 83.1% | 20.4% | 27.3% | 34.8% | 62分 | B |
| 40 | 博瑞医药 | 50.8% | 4.5% | 24.9% | 6.4% | 62分 | B |
| 41 | 苑东生物 | 75.3% | 21.3% | 19.9% | 31.3% | 62分 | B |
| 42 | 必贝特 | 0.0% | 0.0% | 0.0% | 0.0% | 62分 | B |
| 43 | 华东医药 | 32.4% | 7.8% | 4.0% | 15.0% | 62分 | B |
| 44 | 誉衡药业 | 45.3% | 17.6% | 3.7% | 23.2% | 62分 | B |
| 45 | 花园生物 | 55.6% | 24.6% | 5.3% | 11.2% | 62分 | B |
| 46 | 九典制药 | 72.9% | 15.2% | 7.0% | 42.0% | 62分 | B |
| 47 | 梓橦宫 | 76.5% | 19.7% | 1.9% | 44.2% | 61分 | B |
| 48 | 键凯科技 | 63.3% | 19.4% | 17.2% | 4.3% | 61分 | B |
| 49 | 新 和 成 | 44.7% | 30.4% | 4.9% | 0.8% | 61分 | B |
| 50 | 奥赛康 | 80.2% | 13.3% | 8.9% | 51.4% | 61分 | B |
| 51 | 宣泰医药 | 39.4% | 10.6% | 16.8% | 2.2% | 60分 | B |
| 52 | 国药现代 | 32.4% | 10.1% | 4.7% | 5.7% | 60分 | B |
| 53 | 信立泰 | 74.8% | 15.0% | 12.4% | 40.5% | 60分 | B |
| 54 | 同和药业 | 30.3% | 8.8% | 7.8% | 3.5% | 60分 | B |
| 55 | ST人福 | 48.2% | 7.7% | 6.3% | 18.6% | 59分 | B |
| 56 | 哈药股份 | 26.0% | 2.3% | 0.9% | 14.9% | 59分 | B |
| 57 | 科伦药业 | 47.8% | 9.2% | 11.9% | 16.4% | 59分 | B |
| 58 | 普洛药业 | 26.4% | 9.1% | 6.2% | 5.6% | 58分 | B |
| 59 | 通化金马 | 72.1% | 2.9% | 3.4% | 48.0% | 58分 | B |
| 60 | 海思科 | 71.2% | 5.9% | 18.3% | 37.5% | 58分 | B |
| 61 | 海辰药业 | 82.5% | 6.3% | 6.0% | 35.3% | 58分 | B |
| 62 | 西点药业 | 76.3% | 9.3% | 4.8% | 47.8% | 58分 | B |
| 63 | 峆一药业 | 37.1% | 17.4% | 7.1% | 0.8% | 57分 | B |
| 64 | 海正药业 | 44.8% | 5.1% | 4.5% | 19.7% | 57分 | B |
| 65 | 威尔药业 | 28.5% | 11.3% | 6.1% | 1.3% | 57分 | B |
| 66 | 力生制药 | 55.3% | 29.9% | 8.3% | 26.9% | 57分 | B |
| 67 | 东诚药业 | 51.0% | 7.1% | 8.5% | 15.2% | 57分 | B |
| 68 | 科源制药 | 53.4% | 4.2% | 10.6% | 20.2% | 57分 | B |
| 69 | 华纳药厂 | 60.3% | 15.8% | 8.6% | 33.0% | 56分 | B |
| 70 | 新华制药 | 18.8% | 3.3% | 4.4% | 3.9% | 56分 | B |
| 71 | 仙琚制药 | 61.2% | 12.0% | 8.1% | 31.4% | 56分 | B |
| 72 | 昂利康 | 39.5% | 8.8% | 10.1% | 12.0% | 56分 | B |
| 73 | 金石亚药 | 58.3% | 12.7% | 5.3% | 20.2% | 56分 | B |
| 74 | 山河药辅 | 31.8% | 18.7% | 4.5% | 3.2% | 56分 | B |
| 75 | 皓元医药 | 47.1% | 8.3% | 8.3% | 9.7% | 55分 | B |
| 76 | 华润双鹤 | 58.0% | 15.0% | 4.8% | 27.7% | 55分 | B |
| 77 | 健友股份 | 39.4% | 14.6% | 8.7% | 10.2% | 55分 | B |
| 78 | 复星医药 | 50.1% | 8.1% | 9.6% | 22.1% | 54分 | B- |
| 79 | 浙江医药 | 34.7% | 9.8% | 6.5% | 10.1% | 54分 | B- |
| 80 | 津药药业 | 40.9% | 2.4% | 4.5% | 12.3% | 54分 | B- |
| 81 | 东阳光 | 19.9% | 1.8% | 3.8% | 2.0% | 54分 | B- |
| 82 | 圣达生物 | 26.2% | 7.4% | 6.4% | 1.8% | 54分 | B- |
| 83 | 国邦医药 | 26.0% | 13.7% | 3.5% | 1.6% | 54分 | B- |
| 84 | 仟源医药 | 67.4% | 2.9% | 5.8% | 31.3% | 54分 | B- |
| 85 | 辰欣药业 | 51.9% | 12.2% | 8.3% | 25.8% | 53分 | B- |
| 86 | 华邦健康 | 36.9% | 6.2% | 3.0% | 9.8% | 53分 | B- |
| 87 | 亿帆医药 | 46.9% | 7.8% | 5.7% | 22.6% | 53分 | B- |
| 88 | 富士莱 | 16.7% | 14.9% | 8.3% | 1.2% | 53分 | B- |
| 89 | 美诺华 | 35.0% | 6.8% | 7.3% | 5.1% | 52分 | B- |
| 90 | 东北制药 | 37.3% | 3.7% | 2.4% | 17.9% | 52分 | B- |
| 91 | 吉林敖东 | 48.2% | 102.6% | 4.4% | 35.3% | 52分 | B- |
| 92 | 福安药业 | 37.0% | 4.4% | 7.8% | 11.2% | 52分 | B- |
| 93 | 金城医药 | 36.0% | 1.6% | 6.9% | 11.3% | 52分 | B- |
| 94 | 本立科技 | 22.9% | 12.3% | 4.4% | 0.4% | 52分 | B- |
| 95 | 神奇制药 | 45.1% | 2.0% | 1.6% | 31.7% | 51分 | B- |
| 96 | 鲁抗医药 | 22.1% | 1.9% | 5.2% | 7.9% | 51分 | B- |
| 97 | 司太立 | 20.6% | 0.4% | 5.2% | 5.5% | 51分 | B- |
| 98 | 丰原药业 | 18.4% | 2.6% | 1.3% | 8.0% | 51分 | B- |
| 99 | 泰恩康 | 54.1% | 4.2% | 11.5% | 26.7% | 51分 | B- |
| 100 | 永安药业 | 16.9% | 2.9% | 3.9% | 5.1% | 50分 | B- |
| 101 | 北陆药业 | 45.8% | 7.7% | 7.8% | 21.7% | 50分 | B- |
| 102 | 天宇股份 | 37.1% | 4.6% | 7.8% | 6.1% | 50分 | B- |
| 103 | 欧康医药 | 16.4% | 3.5% | 2.9% | 2.3% | 49分 | C+ |
| 104 | 汇宇制药 | 79.6% | -2.5% | 30.3% | 36.0% | 49分 | C+ |
| 105 | 亨迪药业 | 22.1% | 7.7% | 5.5% | 4.6% | 48分 | C+ |
| 106 | 华北制药 | 31.0% | 2.0% | 3.7% | 13.3% | 47分 | C+ |
| 107 | 北大医药 | 28.0% | 5.6% | 1.8% | 7.8% | 47分 | C+ |
| 108 | 能特科技 | 1.9% | 3.4% | 0.8% | 0.2% | 47分 | C+ |
| 109 | 宏源药业 | 18.8% | 6.1% | 4.3% | 2.5% | 47分 | C+ |
| 110 | 亚太药业 | 33.1% | 29.8% | 4.8% | 16.3% | 46分 | C+ |
| 111 | 海普瑞 | 31.8% | 6.4% | 4.1% | 7.8% | 46分 | C+ |
| 112 | 迈威生物 | 90.3% | -146.3% | 147.5% | 34.0% | 45分 | C+ |
| 113 | 亚虹医药 | 74.0% | -150.3% | 102.0% | 98.1% | 45分 | C+ |
| 114 | 迪哲医药 | 95.7% | -95.4% | 106.8% | 71.2% | 45分 | C+ |
| 115 | 首药控股 | 96.9% | -1486.4% | 2269.4% | 0.0% | 45分 | C+ |
| 116 | 泽璟制药 | 90.4% | -20.1% | 53.0% | 57.4% | 45分 | C+ |
| 117 | 海创药业 | 98.6% | -670.5% | 550.6% | 184.1% | 45分 | C+ |
| 118 | 盟科药业 | 84.8% | -170.4% | 150.9% | 63.7% | 45分 | C+ |
| 119 | 益方生物 | 86.5% | -849.7% | 873.7% | 0.0% | 45分 | C+ |
| 120 | 复旦张江 | 89.9% | -23.0% | 52.2% | 57.6% | 45分 | C+ |
| 121 | 百利天恒 | 90.8% | -41.8% | 99.8% | 8.0% | 45分 | C+ |
| 122 | 溢多利 | 45.4% | -2.4% | 12.6% | 20.9% | 43分 | C |
| 123 | *ST景峰 | 62.9% | -21.4% | 2.9% | 43.5% | 41分 | C |
| 124 | 悦康药业 | 50.2% | -10.7% | 18.0% | 28.8% | 39分 | D+ |
| 125 | 广生堂 | 62.3% | -52.3% | 7.7% | 48.8% | 38分 | D+ |
| 126 | 润都股份 | 38.6% | -5.4% | 8.0% | 22.1% | 37分 | D+ |
| 127 | 莱美药业 | 55.8% | -17.4% | 8.1% | 39.9% | 37分 | D+ |
| 128 | 振东制药 | 50.1% | -10.8% | 6.5% | 42.4% | 37分 | D+ |
| 129 | 新诺威 | 38.4% | -11.2% | 48.0% | 13.0% | 37分 | D+ |
| 130 | 莎普爱思 | 46.0% | -51.6% | 5.4% | 19.8% | 35分 | D+ |
| 131 | 康芝药业 | 54.2% | -49.4% | 4.1% | 56.9% | 35分 | D+ |
| 132 | 华仁药业 | 37.0% | -35.0% | 5.1% | 11.4% | 35分 | D+ |
| 133 | 联环药业 | 34.8% | -3.6% | 7.6% | 18.5% | 34分 | D |
| 134 | 罗欣药业 | 49.6% | -12.7% | 4.0% | 40.6% | 34分 | D |
| 135 | 东亚药业 | 23.6% | -8.8% | 9.2% | 1.4% | 31分 | D |
| 136 | 德展健康 | 56.2% | -87.0% | 20.7% | 20.7% | 31分 | D |
| 137 | 一品红 | 56.5% | -36.2% | 16.9% | 34.5% | 31分 | D |
| 138 | 拓新药业 | 26.4% | -18.4% | 11.3% | 2.8% | 29分 | D |
| 139 | 赤天化 | 6.5% | -12.8% | 2.9% | 1.4% | 28分 | D |
| 140 | 海翔药业 | 24.4% | -4.9% | 6.3% | 1.5% | 28分 | D |
| 141 | *ST赛隆 | 14.2% | -23.4% | 3.1% | 4.2% | 27分 | D |
| 142 | 富祥药业 | 16.7% | -4.6% | 5.0% | 1.7% | 27分 | D |
| 143 | 赛托生物 | 15.0% | -7.2% | 4.1% | 1.1% | 27分 | D |
| 144 | 共同药业 | 13.8% | -12.1% | 11.5% | 1.4% | 27分 | D |
| 145 | ST复华 | 32.8% | -30.9% | 4.9% | 17.7% | 26分 | D |
| 146 | 灵康药业 | 43.7% | -59.9% | 3.9% | 48.0% | 26分 | D |
| 147 | 广济药业 | 26.6% | -64.8% | 6.7% | 4.7% | 26分 | D |
| 148 | 哈三联 | 37.7% | -43.0% | 11.8% | 35.5% | 26分 | D |
| 149 | 前沿生物 | 33.2% | -217.2% | 114.7% | 70.3% | 25分 | D |
| 150 | 尔康制药 | 26.4% | -32.6% | 3.9% | 5.1% | 25分 | D |
| 151 | 常山药业 | 15.1% | -40.9% | 3.9% | 5.7% | 23分 | D |
| 152 | 海南海药 | 24.8% | -51.7% | 4.8% | 18.1% | 22分 | D |
| 153 | 南新制药 | 31.5% | -96.5% | 24.9% | 33.1% | 21分 | D |
| 154 | 多瑞医药 | 8.2% | -66.3% | 21.0% | 15.0% | 14分 | D |
医疗器械(137家)
赛道画像:耗材/设备/体外诊断——本行业唯一纯制造段,净利率中位 9.5%、研发费率 10.4%。评分中位57分,毛利率中位52.6%,净利率中位9.5%,35家亏损。
| # | 公司 | 毛利率 | 净利率 | 研发费率 | 销售费率 | 评分 | 等级 |
|---|
| 1 | 安杰思 | 71.1% | 37.3% | 12.8% | 9.4% | 87分 | A |
| 2 | 惠泰医疗 | 72.9% | 31.8% | 14.1% | 17.8% | 82分 | A- |
| 3 | 超研股份 | 71.5% | 36.7% | 12.4% | 13.6% | 82分 | A- |
| 4 | 英诺特 | 78.3% | 34.2% | 22.5% | 15.5% | 81分 | A- |
| 5 | 康拓医疗 | 78.7% | 28.1% | 7.3% | 18.4% | 80分 | A- |
| 6 | 山外山 | 50.2% | 18.1% | 7.8% | 18.7% | 76分 | A- |
| 7 | 海泰新光 | 65.6% | 28.3% | 12.1% | 8.4% | 76分 | A- |
| 8 | 迈瑞医疗 | 60.3% | 24.4% | 10.8% | 15.5% | 75分 | A- |
| 9 | 瑞迈特 | 52.9% | 19.5% | 12.0% | 15.5% | 75分 | A- |
| 10 | 丹娜生物 | 85.5% | 40.3% | 14.2% | 20.2% | 73分 | B+ |
| 11 | 佰仁医疗 | 89.2% | 31.2% | 25.1% | 25.1% | 73分 | B+ |
| 12 | 奕瑞科技 | 51.4% | 28.9% | 15.1% | 3.9% | 73分 | B+ |
| 13 | 西山科技 | 63.7% | 15.2% | 17.0% | 24.4% | 73分 | B+ |
| 14 | 维力医疗 | 44.7% | 4.7% | 7.1% | 10.3% | 73分 | B+ |
| 15 | 心脉医疗 | 71.1% | 41.7% | 5.0% | 15.4% | 72分 | B+ |
| 16 | 鱼跃医疗 | 50.6% | 18.6% | 7.2% | 22.2% | 72分 | B+ |
| 17 | 理邦仪器 | 58.3% | 15.3% | 15.1% | 20.9% | 72分 | B+ |
| 18 | 北芯生命 | 69.9% | 14.8% | 16.3% | 25.3% | 71分 | B+ |
| 19 | 博拓生物 | 46.0% | 11.0% | 18.6% | 8.5% | 71分 | B+ |
| 20 | 福瑞医科 | 75.0% | 9.7% | 7.0% | 24.5% | 71分 | B+ |
| 21 | 艾德生物 | 82.6% | 30.2% | 14.8% | 27.9% | 71分 | B+ |
| 22 | 伟思医疗 | 66.2% | 29.8% | 9.8% | 19.8% | 70分 | B+ |
| 23 | 欧普康视 | 72.5% | 25.8% | 2.4% | 28.0% | 70分 | B+ |
| 24 | 新产业 | 69.3% | 35.4% | 10.4% | 16.1% | 70分 | B+ |
| 25 | 迈普医学 | 80.2% | 30.7% | 10.0% | 18.0% | 70分 | B+ |
| 26 | 健帆生物 | 78.7% | 26.5% | 9.9% | 24.9% | 69分 | B+ |
| 27 | 赛科希德 | 61.7% | 34.0% | 7.3% | 13.4% | 68分 | B+ |
| 28 | 天臣医疗 | 63.9% | 26.1% | 15.7% | 14.6% | 67分 | B+ |
| 29 | 联影医疗 | 47.0% | 13.5% | 13.3% | 16.4% | 67分 | B+ |
| 30 | 安图生物 | 65.6% | 25.3% | 13.1% | 20.1% | 67分 | B+ |
| 31 | 冠昊生物 | 77.1% | 6.3% | 10.6% | 41.5% | 67分 | B+ |
| 32 | 九强生物 | 79.3% | 14.0% | 13.4% | 20.0% | 67分 | B+ |
| 33 | 海圣医疗 | 52.0% | 24.9% | 5.7% | 10.4% | 66分 | B+ |
| 34 | 圣湘生物 | 75.8% | 12.1% | 14.0% | 36.7% | 66分 | B+ |
| 35 | 基蛋生物 | 69.8% | 21.0% | 15.0% | 22.0% | 66分 | B+ |
| 36 | 博迅生物 | 41.3% | 12.4% | 5.5% | 8.4% | 65分 | B+ |
| 37 | 仁度生物 | 78.0% | 6.2% | 21.4% | 48.0% | 65分 | B+ |
| 38 | 普门科技 | 63.2% | 17.8% | 22.0% | 18.0% | 65分 | B+ |
| 39 | 科美诊断 | 66.5% | 13.2% | 22.0% | 18.2% | 65分 | B+ |
| 40 | 中源协和 | 69.8% | 7.8% | 10.2% | 21.0% | 65分 | B+ |
| 41 | 大博医疗 | 70.5% | 23.1% | 12.7% | 26.6% | 65分 | B+ |
| 42 | 三鑫医疗 | 36.0% | 16.2% | 4.6% | 4.7% | 65分 | B+ |
| 43 | 麦澜德 | 70.2% | 23.8% | 14.2% | 23.7% | 64分 | B |
| 44 | 爱迪特 | 52.6% | 19.0% | 7.1% | 19.4% | 64分 | B |
| 45 | 翔宇医疗 | 66.6% | 10.2% | 22.8% | 30.3% | 63分 | B |
| 46 | 戴维医疗 | 53.6% | 14.9% | 10.2% | 17.3% | 63分 | B |
| 47 | 爱得科技 | 58.9% | 25.8% | 7.6% | 12.8% | 62分 | B |
| 48 | 赛诺医疗 | 66.3% | 9.0% | 23.3% | 14.8% | 62分 | B |
| 49 | 海尔生物 | 46.8% | 10.8% | 13.9% | 15.4% | 62分 | B |
| 50 | 奥泰生物 | 50.9% | 24.3% | 12.1% | 8.8% | 62分 | B |
| 51 | 汉邦科技 | 35.6% | 8.1% | 6.2% | 10.0% | 62分 | B |
| 52 | 爱博医疗 | 63.5% | 18.1% | 6.5% | 17.4% | 61分 | B |
| 53 | 可孚医疗 | 53.2% | 11.0% | 2.6% | 34.2% | 61分 | B |
| 54 | 南微医学 | 64.1% | 17.9% | 6.2% | 23.4% | 60分 | B |
| 55 | 亚辉龙 | 64.8% | 1.3% | 16.8% | 24.8% | 60分 | B |
| 56 | 新华医疗 | 25.1% | 5.4% | 4.5% | 9.2% | 60分 | B |
| 57 | 易瑞生物 | 64.0% | 5.2% | 15.8% | 22.1% | 60分 | B |
| 58 | 祥生医疗 | 59.1% | 26.7% | 17.1% | 12.5% | 59分 | B |
| 59 | 黄山胶囊 | 29.7% | 14.1% | 2.8% | 5.4% | 59分 | B |
| 60 | 美康生物 | 36.8% | 4.1% | 8.3% | 14.7% | 59分 | B |
| 61 | 透景生命 | 69.6% | 1.0% | 16.1% | 32.0% | 59分 | B |
| 62 | 正海生物 | 85.9% | 22.6% | 15.7% | 39.1% | 59分 | B |
| 63 | 威高骨科 | 64.9% | 17.6% | 7.4% | 27.8% | 58分 | B |
| 64 | 昊海生科 | 70.1% | 10.1% | 8.0% | 32.9% | 58分 | B |
| 65 | 健信超导 | 27.2% | 13.0% | 6.0% | 0.8% | 58分 | B |
| 66 | 奥美医疗 | 28.6% | 6.8% | 2.8% | 3.0% | 58分 | B |
| 67 | 乐心医疗 | 35.6% | 8.3% | 9.6% | 7.8% | 58分 | B |
| 68 | 英科医疗 | 24.1% | 10.2% | 4.1% | 3.0% | 58分 | B |
| 69 | 鹿得医疗 | 25.7% | 6.5% | 5.0% | 8.3% | 57分 | B |
| 70 | 三友医疗 | 74.9% | 11.6% | 15.4% | 32.7% | 57分 | B |
| 71 | 微电生理 | 58.0% | 11.0% | 13.8% | 28.7% | 57分 | B |
| 72 | 振德医疗 | 33.9% | 6.0% | 3.3% | 8.4% | 57分 | B |
| 73 | 乐普医疗 | 64.0% | 14.8% | 12.2% | 18.0% | 57分 | B |
| 74 | 阳普医疗 | 43.0% | 3.0% | 4.9% | 13.6% | 57分 | B |
| 75 | 澳华内镜 | 65.2% | 1.5% | 19.0% | 31.1% | 56分 | B |
| 76 | 山东药玻 | 33.3% | 15.4% | 3.9% | 2.4% | 56分 | B |
| 77 | 五洲医疗 | 14.6% | 4.1% | 2.1% | 4.0% | 56分 | B |
| 78 | 爱舍伦 | 22.3% | 9.5% | 1.1% | 1.3% | 55分 | B |
| 79 | 锦好医疗 | 37.6% | 5.0% | 6.9% | 15.8% | 55分 | B |
| 80 | 威高血净 | 40.2% | 12.8% | 3.8% | 16.5% | 55分 | B |
| 81 | 美好医疗 | 40.1% | 17.4% | 8.2% | 2.9% | 55分 | B |
| 82 | 正川股份 | 18.3% | 2.8% | 2.2% | 2.7% | 54分 | B- |
| 83 | 九安医疗 | 63.8% | 166.0% | 23.7% | 27.2% | 53分 | B- |
| 84 | 国科恒泰 | 10.6% | 1.0% | 0.1% | 4.9% | 53分 | B- |
| 85 | 奥精医疗 | 68.7% | 6.2% | 17.5% | 24.9% | 51分 | B- |
| 86 | 东富龙 | 29.3% | 3.8% | 6.5% | 5.5% | 51分 | B- |
| 87 | 健尔康 | 24.8% | 10.9% | 4.0% | 2.8% | 50分 | B- |
| 88 | 三诺生物 | 48.7% | 2.0% | 5.9% | 27.0% | 50分 | B- |
| 89 | 采纳股份 | 22.4% | 1.6% | 6.2% | 2.5% | 50分 | B- |
| 90 | 爱威科技 | 60.5% | 13.1% | 12.4% | 28.7% | 49分 | C+ |
| 91 | 浩欧博 | 58.4% | 5.8% | 12.0% | 24.3% | 49分 | C+ |
| 92 | 拱东医疗 | 27.9% | 4.5% | 4.0% | 4.9% | 49分 | C+ |
| 93 | 楚天科技 | 32.2% | 4.4% | 8.4% | 10.4% | 49分 | C+ |
| 94 | 华兰股份 | 38.9% | 9.7% | 6.4% | 8.0% | 49分 | C+ |
| 95 | 康德莱 | 33.1% | 10.5% | 3.9% | 8.1% | 48分 | C+ |
| 96 | 开立医疗 | 62.0% | 8.5% | 21.5% | 29.3% | 48分 | C+ |
| 97 | 安旭生物 | 42.5% | 15.4% | 17.4% | 11.6% | 46分 | C+ |
| 98 | ST凯利 | 53.7% | 14.0% | 5.3% | 17.7% | 46分 | C+ |
| 99 | 华康洁净 | 32.8% | 5.2% | 3.5% | 7.7% | 45分 | C+ |
| 100 | 中科美菱 | 36.1% | 6.2% | 10.1% | 14.1% | 44分 | C |
| 101 | 睿昂基因 | 75.4% | -28.4% | 29.9% | 26.9% | 44分 | C |
| 102 | 天智航 | 69.2% | -65.5% | 44.2% | 54.0% | 44分 | C |
| 103 | 力诺药包 | 21.1% | 4.0% | 3.5% | 6.3% | 43分 | C |
| 104 | 天益医疗 | 43.0% | -2.8% | 9.9% | 5.7% | 42分 | C |
| 105 | 华强科技 | 24.9% | 6.8% | 9.3% | 4.5% | 41分 | C |
| 106 | 之江生物 | 64.2% | -27.5% | 40.8% | 40.3% | 39分 | D+ |
| 107 | 迈克生物 | 59.0% | -1.7% | 14.7% | 31.5% | 39分 | D+ |
| 108 | 东星医疗 | 48.6% | -9.8% | 5.4% | 12.0% | 39分 | D+ |
| 109 | 爱朋医疗 | 68.4% | -7.0% | 11.9% | 44.7% | 37分 | D+ |
| 110 | 康泰医学 | 48.0% | -5.2% | 19.6% | 23.5% | 37分 | D+ |
| 111 | 华大智造 | 52.9% | -8.0% | 19.4% | 25.2% | 36分 | D+ |
| 112 | 硕世生物 | 63.2% | -12.1% | 23.2% | 37.9% | 36分 | D+ |
| 113 | 万孚生物 | 57.0% | -3.0% | 16.1% | 31.6% | 34分 | D |
| 114 | 华大基因 | 37.6% | -16.6% | 12.3% | 20.9% | 33分 | D |
| 115 | 辰光医疗 | 52.1% | -67.2% | 36.4% | 26.4% | 32分 | D |
| 116 | 热景生物 | 57.6% | -53.4% | 40.1% | 54.5% | 32分 | D |
| 117 | 安必平 | 63.6% | -13.7% | 10.5% | 47.9% | 32分 | D |
| 118 | 万东医疗 | 26.6% | -16.9% | 19.5% | 20.6% | 31分 | D |
| 119 | 贝瑞基因 | 43.1% | -21.2% | 11.2% | 22.2% | 30分 | D |
| 120 | 康众医疗 | 36.6% | -2.1% | 10.0% | 9.8% | 29分 | D |
| 121 | 博晖创新 | 39.6% | -11.1% | 7.9% | 12.8% | 29分 | D |
| 122 | 迪瑞医疗 | 40.6% | -30.5% | 15.1% | 28.9% | 29分 | D |
| 123 | 万泰生物 | 49.3% | -21.9% | 30.8% | 24.5% | 27分 | D |
| 124 | 南卫股份 | 3.9% | -16.9% | 4.8% | 0.9% | 27分 | D |
| 125 | 蓝帆医疗 | 15.7% | -13.2% | 4.4% | 8.5% | 27分 | D |
| 126 | 尚荣医疗 | 11.9% | -13.0% | 3.9% | 1.8% | 27分 | D |
| 127 | 宝莱特 | 25.7% | -6.3% | 6.4% | 11.8% | 27分 | D |
| 128 | 利德曼 | 50.1% | -7.0% | 7.4% | 24.1% | 27分 | D |
| 129 | 中红医疗 | 11.1% | -4.7% | 2.1% | 4.9% | 27分 | D |
| 130 | 东方生物 | 40.8% | -60.5% | 24.4% | 20.2% | 24分 | D |
| 131 | 康为世纪 | 45.4% | -55.5% | 40.0% | 44.7% | 24分 | D |
| 132 | 济民健康 | 31.0% | -35.8% | 7.0% | 20.3% | 24分 | D |
| 133 | 凯普生物 | 45.5% | -19.6% | 9.3% | 24.9% | 23分 | D |
| 134 | 港通医疗 | 22.7% | -0.4% | 3.6% | 5.4% | 23分 | D |
| 135 | 科华生物 | 35.1% | -44.6% | 11.5% | 23.7% | 18分 | D |
| 136 | 明德生物 | 36.2% | -6.2% | 32.4% | 27.8% | 18分 | D |
| 137 | 达安基因 | 32.4% | -98.2% | 24.6% | 29.5% | 16分 | D |
中药Ⅱ(68家)
赛道画像:中药制造与品牌——中药材采购是成本主项,销售费率中位 31.8%(品牌驱动)。评分中位55分,毛利率中位54.3%,净利率中位7.2%,14家亏损。
| # | 公司 | 毛利率 | 净利率 | 研发费率 | 销售费率 | 评分 | 等级 |
|---|
| 1 | 桂林三金 | 76.0% | 21.2% | 7.8% | 32.9% | 85分 | A |
| 2 | 东阿阿胶 | 73.5% | 25.9% | 4.1% | 32.0% | 82分 | A- |
| 3 | 华润江中 | 65.4% | 21.5% | 3.6% | 30.8% | 76分 | A- |
| 4 | 马应龙 | 49.2% | 15.0% | 2.0% | 26.2% | 75分 | A- |
| 5 | 济川药业 | 79.0% | 28.6% | 6.2% | 33.9% | 74分 | B+ |
| 6 | 以岭药业 | 64.3% | 16.4% | 9.2% | 25.1% | 73分 | B+ |
| 7 | 奇正藏药 | 83.1% | 26.8% | 3.4% | 45.3% | 71分 | B+ |
| 8 | 上海凯宝 | 80.7% | 24.2% | 7.7% | 42.8% | 71分 | B+ |
| 9 | 佐力药业 | 61.6% | 20.8% | 2.3% | 31.6% | 71分 | B+ |
| 10 | 羚锐制药 | 80.0% | 19.7% | 4.4% | 47.5% | 70分 | B+ |
| 11 | 精华制药 | 51.9% | 15.0% | 4.5% | 18.3% | 69分 | B+ |
| 12 | 千金药业 | 48.8% | 7.9% | 5.1% | 24.1% | 68分 | B+ |
| 13 | 方盛制药 | 72.0% | 17.5% | 8.8% | 34.6% | 67分 | B+ |
| 14 | 天士力 | 66.9% | 13.4% | 8.3% | 36.1% | 65分 | B+ |
| 15 | 西藏药业 | 94.2% | 31.5% | 2.5% | 55.1% | 64分 | B |
| 16 | 亚宝药业 | 52.5% | 14.3% | 5.2% | 20.2% | 64分 | B |
| 17 | 汉森制药 | 77.4% | 19.1% | 3.8% | 41.4% | 64分 | B |
| 18 | 新光药业 | 38.8% | 20.4% | 5.0% | 7.6% | 63分 | B |
| 19 | 达仁堂 | 74.0% | 43.3% | 3.9% | 41.2% | 62分 | B |
| 20 | 康缘药业 | 71.4% | 9.2% | 18.4% | 33.9% | 62分 | B |
| 21 | 健民集团 | 58.4% | 10.7% | 2.9% | 43.1% | 62分 | B |
| 22 | 寿仙谷 | 78.7% | 2.8% | 8.1% | 41.1% | 62分 | B |
| 23 | 康恩贝 | 53.3% | 7.3% | 4.0% | 31.2% | 61分 | B |
| 24 | 沃华医药 | 75.4% | 11.7% | 4.5% | 49.9% | 60分 | B |
| 25 | 金花股份 | 77.0% | 2.9% | 5.7% | 60.0% | 59分 | B |
| 26 | 天目药业 | 47.8% | 8.3% | 0.0% | 6.4% | 59分 | B |
| 27 | 陇神戎发 | 68.3% | 5.0% | 3.1% | 46.5% | 58分 | B |
| 28 | 仁和药业 | 37.0% | 11.1% | 1.3% | 9.8% | 57分 | B |
| 29 | 金陵药业 | 20.9% | 1.7% | 3.4% | 4.4% | 57分 | B |
| 30 | 太极集团 | 29.6% | 1.1% | 2.5% | 15.7% | 56分 | B |
| 31 | 云南白药 | 29.5% | 12.5% | 0.8% | 13.6% | 56分 | B |
| 32 | 盘龙药业 | 51.9% | 8.4% | 4.7% | 30.6% | 56分 | B |
| 33 | 片仔癀 | 36.4% | 24.0% | 2.8% | 4.5% | 55分 | B |
| 34 | 广誉远 | 67.6% | 4.6% | 2.8% | 46.6% | 55分 | B |
| 35 | 三力制药 | 70.0% | 2.7% | 1.6% | 47.0% | 55分 | B |
| 36 | 九芝堂 | 59.9% | 10.0% | 6.5% | 31.0% | 55分 | B |
| 37 | 华润三九 | 54.0% | 10.8% | 4.0% | 28.8% | 55分 | B |
| 38 | 嘉应制药 | 59.9% | 7.9% | 2.4% | 35.6% | 55分 | B |
| 39 | 华森制药 | 57.4% | 7.9% | 10.8% | 30.8% | 54分 | B- |
| 40 | 恩威医药 | 49.5% | 5.8% | 0.6% | 33.4% | 54分 | B- |
| 41 | 太龙药业 | 28.0% | 3.4% | 3.9% | 7.5% | 53分 | B- |
| 42 | 同仁堂 | 42.9% | 6.9% | 1.7% | 20.5% | 52分 | B- |
| 43 | 莱茵生物 | 25.8% | 7.0% | 2.9% | 3.7% | 52分 | B- |
| 44 | 佛慈制药 | 34.1% | 5.4% | 2.7% | 11.2% | 52分 | B- |
| 45 | 益盛药业 | 74.0% | 4.5% | 2.4% | 49.6% | 51分 | B- |
| 46 | 步长制药 | 62.9% | 3.0% | 2.0% | 40.7% | 50分 | B- |
| 47 | 信邦制药 | 17.6% | 2.1% | 0.1% | 4.5% | 50分 | B- |
| 48 | 特一药业 | 54.6% | 8.8% | 4.8% | 32.4% | 50分 | B- |
| 49 | 新天药业 | 71.6% | 1.2% | 5.7% | 43.9% | 50分 | B- |
| 50 | 昆药集团 | 38.5% | 5.3% | 1.6% | 26.0% | 49分 | C+ |
| 51 | 众生药业 | 56.1% | 10.9% | 3.6% | 34.5% | 49分 | C+ |
| 52 | 红日药业 | 58.3% | 0.4% | 4.0% | 38.1% | 49分 | C+ |
| 53 | 康美药业 | 20.0% | 0.2% | 0.9% | 10.0% | 48分 | C+ |
| 54 | 白云山 | 16.2% | 3.8% | 0.8% | 7.5% | 45分 | C+ |
| 55 | 粤万年青 | 60.7% | -1.4% | 2.7% | 46.6% | 35分 | D+ |
| 56 | ST百灵 | 47.4% | -3.4% | 0.6% | 33.2% | 34分 | D |
| 57 | 古汉医药 | 44.8% | -15.0% | 4.1% | 18.4% | 33分 | D |
| 58 | 生物谷 | 61.1% | -11.9% | 1.3% | 49.4% | 32分 | D |
| 59 | 益佰制药 | 59.7% | -17.7% | 4.5% | 44.2% | 30分 | D |
| 60 | 葵花药业 | 38.2% | -11.1% | 4.8% | 25.0% | 29分 | D |
| 61 | 大唐药业 | 52.5% | -62.4% | 9.4% | 69.4% | 28分 | D |
| 62 | 中恒集团 | 44.1% | -20.4% | 7.2% | 28.1% | 28分 | D |
| 63 | ST葫芦娃 | 29.3% | -31.9% | 10.4% | 25.7% | 28分 | D |
| 64 | ST香雪 | 27.3% | -87.3% | 4.5% | 10.0% | 27分 | D |
| 65 | 康惠股份 | 25.4% | -70.8% | 2.6% | 28.6% | 26分 | D |
| 66 | 华神科技 | 47.6% | -58.7% | 4.3% | 44.1% | 24分 | D |
| 67 | 珍宝岛 | -2.8% | -171.2% | 5.8% | 16.6% | 18分 | D |
| 68 | 维康药业 | 31.1% | -100.9% | 4.2% | 47.5% | 14分 | D |
生物制品(55家)
赛道画像:疫苗/血制品/生物药——毛利率中位 69.5% 但销售费率 30.1%、研发费率 12.2%,现金周期 271 天。评分中位52分,毛利率中位69.5%,净利率中位5.5%,20家亏损。
| # | 公司 | 毛利率 | 净利率 | 研发费率 | 销售费率 | 评分 | 等级 |
|---|
| 1 | 三生国健 | 92.1% | 69.0% | 10.4% | 4.7% | 87分 | A |
| 2 | 安科生物 | 75.7% | 27.8% | 8.3% | 30.1% | 76分 | A- |
| 3 | 百普赛斯 | 91.2% | 19.8% | 22.0% | 29.7% | 73分 | B+ |
| 4 | 特宝生物 | 93.0% | 27.9% | 10.5% | 39.3% | 72分 | B+ |
| 5 | 我武生物 | 95.2% | 35.9% | 11.0% | 37.4% | 72分 | B+ |
| 6 | 欧林生物 | 93.0% | 3.2% | 18.9% | 54.1% | 71分 | B+ |
| 7 | 赛伦生物 | 78.1% | 26.4% | 9.9% | 28.1% | 69分 | B+ |
| 8 | 凯因科技 | 82.2% | 2.3% | 10.7% | 47.6% | 68分 | B+ |
| 9 | 万泽股份 | 71.7% | 15.3% | 16.4% | 28.0% | 67分 | B+ |
| 10 | 甘李药业 | 75.8% | 28.2% | 16.0% | 33.3% | 66分 | B+ |
| 11 | 无锡晶海 | 30.7% | 15.6% | 4.4% | 3.0% | 65分 | B+ |
| 12 | 三元基因 | 78.2% | 1.8% | 8.6% | 46.8% | 62分 | B |
| 13 | 成大生物 | 79.4% | 9.5% | 21.1% | 27.3% | 62分 | B |
| 14 | 康希诺 | 77.5% | 2.6% | 29.3% | 39.0% | 61分 | B |
| 15 | 康华生物 | 92.0% | 18.9% | 10.2% | 47.9% | 61分 | B |
| 16 | 科兴制药 | 63.4% | 10.1% | 13.0% | 37.4% | 58分 | B |
| 17 | 康泰生物 | 74.7% | 2.6% | 20.3% | 33.5% | 58分 | B |
| 18 | 天坛生物 | 43.9% | 17.7% | 2.6% | 2.0% | 57分 | B |
| 19 | 长春高新 | 82.1% | 1.3% | 20.5% | 42.1% | 57分 | B |
| 20 | 康辰药业 | 89.9% | 18.1% | 5.7% | 46.9% | 56分 | B |
| 21 | 卫光生物 | 39.4% | 19.4% | 3.6% | 2.9% | 56分 | B |
| 22 | 奥浦迈 | 50.8% | 11.7% | 13.6% | 9.0% | 55分 | B |
| 23 | 沃森生物 | 74.6% | 7.4% | 12.1% | 35.3% | 55分 | B |
| 24 | 华兰生物 | 57.5% | 20.5% | 7.3% | 17.8% | 54分 | B- |
| 25 | 华兰疫苗 | 77.8% | 15.2% | 12.6% | 45.3% | 54分 | B- |
| 26 | 昊帆生物 | 34.8% | 19.0% | 6.8% | 2.7% | 54分 | B- |
| 27 | 通化东宝 | 70.3% | 41.4% | 5.7% | 37.6% | 52分 | B- |
| 28 | 东宝生物 | 23.4% | 7.3% | 3.4% | 2.6% | 52分 | B- |
| 29 | 赛升药业 | 65.1% | 3.6% | 17.2% | 35.7% | 52分 | B- |
| 30 | 义翘神州 | 73.3% | 21.1% | 12.3% | 23.3% | 52分 | B- |
| 31 | 辽宁成大 | 13.0% | 7.4% | 3.0% | 5.7% | 50分 | B- |
| 32 | 派林生物 | 41.5% | 15.9% | 2.1% | 9.2% | 49分 | C+ |
| 33 | 上海莱士 | 37.4% | 21.5% | 3.0% | 4.6% | 48分 | C+ |
| 34 | *ST双成 | 54.7% | 6.9% | 2.9% | 11.0% | 46分 | C+ |
| 35 | 博雅生物 | 49.9% | 5.5% | 2.6% | 20.0% | 46分 | C+ |
| 36 | 百奥泰 | 78.9% | -35.5% | 85.6% | 30.4% | 45分 | C+ |
| 37 | 君实生物 | 81.3% | -35.0% | 53.7% | 42.1% | 45分 | C+ |
| 38 | 智翔金泰 | 93.0% | -232.2% | 204.9% | 105.6% | 45分 | C+ |
| 39 | 神州细胞 | 93.1% | -36.2% | 53.7% | 54.0% | 45分 | C+ |
| 40 | 舒泰神 | 77.3% | -35.3% | 38.6% | 55.3% | 42分 | C |
| 41 | 艾迪药业 | 66.8% | -2.7% | 12.2% | 34.2% | 40分 | C |
| 42 | 诺唯赞 | 69.5% | -1.2% | 20.4% | 37.0% | 35分 | D+ |
| 43 | 双鹭药业 | 62.1% | -55.7% | 18.5% | 17.9% | 34分 | D |
| 44 | 诺思兰德 | 56.3% | -80.8% | 64.8% | 21.1% | 30分 | D |
| 45 | 百克生物 | 73.4% | -43.4% | 29.3% | 64.3% | 30分 | D |
| 46 | 南京新百 | 40.5% | -13.2% | 3.6% | 8.8% | 30分 | D |
| 47 | 近岸蛋白 | 67.1% | -53.1% | 43.8% | 38.8% | 27分 | D |
| 48 | 金迪克 | 64.4% | -158.1% | 81.3% | 59.0% | 27分 | D |
| 49 | 海特生物 | 42.6% | -42.7% | 16.3% | 28.8% | 27分 | D |
| 50 | 优宁维 | 18.8% | -2.1% | 6.2% | 11.7% | 27分 | D |
| 51 | 康乐卫士 | 49.9% | -39978.8% | 11411.1% | 0.0% | 26分 | D |
| 52 | *ST四环 | 37.3% | -10.8% | 9.4% | 18.5% | 25分 | D |
| 53 | 智飞生物 | 7.8% | -164.3% | 10.4% | 26.6% | 23分 | D |
| 54 | ST未名 | 52.8% | -42.3% | 6.9% | 50.8% | 20分 | D |
| 55 | 禾元生物 | 37.1% | -328.1% | 193.6% | 18.2% | 15分 | D |
医疗服务(49家)
赛道画像:医院/诊断/CXO——服务型,成本 = 人力 + 设备折旧(成本率中位 65.3%、管理费率 12.2%)。评分中位57分,毛利率中位34.7%,净利率中位6.9%,14家亏损。
| # | 公司 | 毛利率 | 净利率 | 研发费率 | 销售费率 | 评分 | 等级 |
|---|
| 1 | 药明康德 | 47.6% | 42.1% | 2.5% | 1.8% | 85分 | A |
| 2 | 百花医药 | 45.5% | 10.5% | 6.3% | 3.1% | 77分 | A- |
| 3 | 九洲药业 | 36.9% | 13.3% | 4.7% | 2.0% | 77分 | A- |
| 4 | 阳光诺和 | 54.1% | 16.7% | 13.2% | 4.3% | 74分 | B+ |
| 5 | 华厦眼科 | 43.3% | 10.6% | 1.5% | 13.8% | 71分 | B+ |
| 6 | 南模生物 | 51.7% | 7.5% | 20.6% | 14.4% | 69分 | B+ |
| 7 | ST诺泰 | 62.6% | 17.1% | 13.0% | 5.0% | 68分 | B+ |
| 8 | 成都先导 | 54.2% | 20.8% | 13.6% | 4.3% | 67分 | B+ |
| 9 | 通策医疗 | 38.6% | 17.2% | 2.1% | 1.2% | 67分 | B+ |
| 10 | 诺思格 | 34.7% | 16.1% | 7.3% | 1.6% | 67分 | B+ |
| 11 | 百奥赛图 | 75.8% | 12.6% | 31.8% | 9.6% | 66分 | B+ |
| 12 | 盈康生命 | 27.1% | 3.6% | 2.6% | 2.5% | 65分 | B+ |
| 13 | 康龙化成 | 34.8% | 11.8% | 4.1% | 2.2% | 64分 | B |
| 14 | 金凯生科 | 42.5% | 16.4% | 5.6% | 3.9% | 64分 | B |
| 15 | 药康生物 | 64.1% | 18.0% | 11.6% | 14.1% | 62分 | B |
| 16 | 泰格医药 | 27.4% | 13.0% | 3.8% | 3.4% | 62分 | B |
| 17 | 毕得医药 | 44.5% | 11.5% | 4.7% | 11.4% | 61分 | B |
| 18 | 爱尔眼科 | 47.1% | 14.5% | 1.4% | 9.6% | 61分 | B |
| 19 | 新里程 | 28.8% | 1.0% | 0.4% | 6.7% | 60分 | B |
| 20 | 凯莱英 | 42.0% | 17.0% | 8.9% | 3.2% | 60分 | B |
| 21 | 博腾股份 | 29.9% | 2.8% | 7.8% | 5.1% | 59分 | B |
| 22 | 普蕊斯 | 25.9% | 13.0% | 4.6% | 1.1% | 59分 | B |
| 23 | 药石科技 | 30.8% | 9.3% | 5.5% | 3.4% | 58分 | B |
| 24 | 数字人 | 69.5% | 8.2% | 27.0% | 26.5% | 57分 | B |
| 25 | 诺禾致源 | 42.5% | 7.6% | 7.2% | 20.1% | 57分 | B |
| 26 | 美年健康 | 41.4% | 2.8% | 0.5% | 22.6% | 56分 | B |
| 27 | 博济医药 | 27.1% | 3.5% | 6.6% | 6.5% | 55分 | B |
| 28 | 何氏眼科 | 41.0% | 2.5% | 1.5% | 16.2% | 55分 | B |
| 29 | 泓博医药 | 27.4% | 5.0% | 5.4% | 2.0% | 52分 | B- |
| 30 | 三博脑科 | 23.3% | 4.9% | 0.0% | 2.2% | 52分 | B- |
| 31 | 睿智医药 | 28.6% | 1.2% | 5.3% | 5.4% | 49分 | C+ |
| 32 | 万邦医药 | 25.9% | 13.3% | 12.0% | 2.1% | 49分 | C+ |
| 33 | 迪安诊断 | 28.5% | 0.4% | 2.5% | 11.5% | 46分 | C+ |
| 34 | 诚达药业 | 44.2% | -2.9% | 9.9% | 1.1% | 46分 | C+ |
| 35 | 百诚医药 | 39.5% | -13.3% | 28.0% | 1.5% | 43分 | C |
| 36 | *ST生物 | 22.1% | 6.9% | 1.8% | 5.3% | 42分 | C |
| 37 | 光正眼科 | 36.3% | -2.2% | 0.5% | 19.2% | 38分 | D+ |
| 38 | 金域医学 | 34.7% | -2.9% | 5.7% | 14.5% | 35分 | D+ |
| 39 | 普瑞眼科 | 35.9% | -2.2% | 0.4% | 18.5% | 35分 | D+ |
| 40 | 昭衍新药 | 20.7% | 18.0% | 5.3% | 2.2% | 34分 | D |
| 41 | 益诺思 | 26.0% | -3.8% | 5.6% | 3.9% | 29分 | D |
| 42 | 华塑控股 | 6.7% | -1.4% | 1.0% | 0.5% | 28分 | D |
| 43 | 创新医疗 | 6.9% | -4.5% | 0.4% | 1.1% | 28分 | D |
| 44 | 美迪西 | 17.4% | -14.4% | 9.0% | 7.7% | 27分 | D |
| 45 | 国际医学 | 8.3% | -7.7% | 0.2% | 1.3% | 27分 | D |
| 46 | 兰卫医学 | 24.0% | -2.1% | 2.8% | 5.8% | 27分 | D |
| 47 | 润达医疗 | 21.4% | -7.8% | 1.5% | 10.7% | 24分 | D |
| 48 | ST中珠 | 17.9% | -19.8% | 2.1% | 4.7% | 20分 | D |
| 49 | 和元生物 | -14.5% | -87.8% | 18.2% | 18.5% | 15分 | D |
医药商业(33家)
赛道画像:流通与零售药房——成本率中位 89.0%、毛利率 11.0%,降本靠仓配与周转(黄金线 0/33)。评分中位52分,毛利率中位11.0%,净利率中位1.3%,7家亏损。
| # | 公司 | 毛利率 | 净利率 | 研发费率 | 销售费率 | 评分 | 等级 |
|---|
| 1 | 益丰药房 | 39.4% | 6.9% | 0.1% | 24.0% | 66分 | B+ |
| 2 | 华人健康 | 33.9% | 3.5% | 0.5% | 21.4% | 66分 | B+ |
| 3 | 百洋医药 | 37.5% | 6.3% | 0.6% | 21.6% | 64分 | B |
| 4 | 第一医药 | 16.0% | 2.7% | 0.0% | 12.6% | 62分 | B |
| 5 | 大参林 | 34.3% | 4.5% | 0.1% | 21.9% | 62分 | B |
| 6 | 一心堂 | 32.6% | 1.5% | 0.1% | 25.9% | 59分 | B |
| 7 | 开开实业 | 15.4% | 1.1% | 0.0% | 5.9% | 58分 | B |
| 8 | 柳药集团 | 11.0% | 3.4% | 0.2% | 3.2% | 57分 | B |
| 9 | 健之佳 | 36.1% | 1.7% | 0.0% | 28.8% | 57分 | B |
| 10 | 浙江震元 | 24.9% | 1.0% | 2.1% | 15.2% | 57分 | B |
| 11 | 浙农股份 | 5.9% | 1.2% | 0.0% | 1.7% | 57分 | B |
| 12 | 九州通 | 7.8% | 1.4% | 0.1% | 3.1% | 56分 | B |
| 13 | 老百姓 | 32.3% | 1.7% | 0.2% | 21.1% | 56分 | B |
| 14 | 国药股份 | 6.6% | 3.8% | 0.1% | 1.4% | 54分 | B- |
| 15 | 漱玉平民 | 26.2% | 1.1% | 0.0% | 20.7% | 54分 | B- |
| 16 | 瑞康医药 | 10.6% | 0.2% | 0.3% | 4.5% | 53分 | B- |
| 17 | 国药一致 | 10.7% | 1.5% | 0.0% | 6.6% | 52分 | B- |
| 18 | 建发致新 | 7.9% | 1.4% | 0.1% | 3.0% | 52分 | B- |
| 19 | 上海医药 | 10.7% | 2.0% | 0.8% | 4.7% | 51分 | B- |
| 20 | 南京医药 | 6.2% | 1.1% | 0.1% | 2.2% | 49分 | C+ |
| 21 | 英特集团 | 7.0% | 1.5% | 0.1% | 2.8% | 49分 | C+ |
| 22 | 嘉事堂 | 6.4% | 0.6% | 0.0% | 1.3% | 49分 | C+ |
| 23 | 鹭燕医药 | 7.1% | 1.3% | 0.0% | 2.4% | 48分 | C+ |
| 24 | 达嘉维康 | 18.2% | -4.7% | 0.2% | 12.6% | 48分 | C+ |
| 25 | 中国医药 | 10.5% | 1.3% | 0.5% | 2.9% | 47分 | C+ |
| 26 | 人民同泰 | 8.2% | 1.3% | 0.0% | 4.3% | 47分 | C+ |
| 27 | 重药控股 | 7.2% | 0.5% | 0.0% | 2.6% | 45分 | C+ |
| 28 | ST天圣 | 49.1% | -10.8% | 4.3% | 30.8% | 45分 | C+ |
| 29 | 国发股份 | 22.5% | -26.7% | 2.2% | 9.3% | 41分 | C |
| 30 | 药易购 | 10.4% | -0.3% | 0.2% | 7.3% | 41分 | C |
| 31 | 塞力医疗 | 22.3% | -19.2% | 3.9% | 8.5% | 37分 | D+ |
| 32 | 合富中国 | 14.8% | -5.0% | 0.6% | 8.9% | 34分 | D |
| 33 | 海王生物 | 9.2% | -2.1% | 0.1% | 3.5% | 33分 | D |
想了解你在细分赛道的排名?
华为系成本顾问免费上门诊断
预约免费诊断
免责声明:本报告基于上市公司公开年报数据,采用华师华成本管理框架进行分析,仅供成本管理研究参考,不构成任何投资建议。数据可能存在滞后或偏差,请以公司公告为准。